Center for Scientific Review; Notice of Closed Meetings, 60894 [2021-24053]
Download as PDF
<![CDATA[
60894
Federal Register / Vol. 86, No. 211 / Thursday, November 4, 2021 / Notices
and Hematology Research, National Institutes
of Health, HHS)
Dated: October 29, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–24029 Filed 11–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Fogarty HIV Research Training Program for
Low- and Middle-Income Country
Institutions.
Date: December 2–3, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maureen Shuh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–480–4097,
maureen.shuh@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Genes, Genomes and Genetics.
Date: December 6, 2021.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elena Smirnova, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5187,
MSC 7840, Bethesda, MD 20892, 301–357–
9112, smirnove@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics
Focused on Alzheimer’s Disease and
Alzheimer’s-Related Dementia.
VerDate Sep<11>2014
17:57 Nov 03, 2021
Jkt 256001
Date: December 7–8, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Tara Roshell Earl, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007C,
Bethesda, MD 20892, (301) 451–3946, earltr@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Respiratory Sciences.
Date: December 13–14, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ghenima Dirami, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4122,
MSC 7814, Bethesda, MD 20892, (240) 498–
7546, diramig@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 31, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–24053 Filed 11–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Soukas, J.D., 301–496–2644;
peter.soukas@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
SUMMARY:
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Recombinant Chimeric Bovine/Human
Parainfluenza Virus 3 Expressing
SARS–CoV–2 Spike Protein and Its Use
Description of Technology
Vaccines for SARS–CoV–2 are
increasingly available under emergency
use authorizations; however, indications
are currently limited to individuals
twelve (12) years or older. They also
involve intramuscular immunization,
which does not directly stimulate local
immunity in the respiratory tract, the
primary site of SARS–CoV–2 infection,
shedding and spread. While the major
burden of COVID–19 disease is in
adults, infection and disease also occur
in infants and young children,
contributing to viral transmission.
Therefore, the development of safe and
effective pediatric COVID–19 vaccines
is important. Ideally, a vaccine should
be effective as a single dose, should
induce mucosal immunity with the
ability to restrict SARS–CoV–2 infection
and respiratory shedding, and should
easily coordinate with vaccines for other
illnesses, such as HPIV3.
The live-attenuated vaccine
candidates are based on a recombinant
chimeric bovine/human parainfluenza
virus 3 (rB/HPIV3) vector expressing
prefusion-stabilized versions of the
Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS–CoV–2) Spike (S)
protein. The B/HPIV3–SARS CoV–2
vaccine candidates are designed to be
administered intranasally by drops or
spray to infants and young children.
The vaccines are expected to induce
durable and broad systemic and
respiratory mucosal immunity against
SARS–CoV–2 and HPIV3.
Immunogenicity and protective efficacy
against SARS–CoV–2 challenge was
confirmed in experimental animals
including non-human primates. Based
on experience with this B/HPIV3
platform and other live-attenuated PIV
vaccine candidates in previous pediatric
clinical studies, the present candidates
are anticipated to be well-tolerated in
humans, including infants and young
children, and are available for clinical
evaluation. The National Institute of
Allergy and Infectious Diseases has
extensive experience and capability in
E:\FR\FM\04NON1.SGM
04NON1
]]>Agencies
[Federal Register Volume 86, Number 211 (Thursday, November 4, 2021)]
[Notices]
[Page 60894]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-24053]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Fogarty HIV Research Training Program for Low- and
Middle-Income Country Institutions.
Date: December 2-3, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maureen Shuh, Ph.D., Scientific Review Officer,
Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD
20892, 301-480-4097, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Genes, Genomes and Genetics.
Date: December 6, 2021.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elena Smirnova, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5187, MSC 7840, Bethesda, MD
20892, 301-357-9112, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Topics Focused on Alzheimer's Disease and Alzheimer's-Related
Dementia.
Date: December 7-8, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Tara Roshell Earl, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007C, Bethesda, MD 20892, (301)
451-3946, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Respiratory Sciences.
Date: December 13-14, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ghenima Dirami, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4122, MSC 7814, Bethesda, MD
20892, (240) 498-7546, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: October 31, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-24053 Filed 11-3-21; 8:45 am]
BILLING CODE 4140-01-P
